Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients

British Journal of Clinical Pharmacology

Volumn 44, Issue 6, 1997, Pages 591-594

  Simon, Nicolas ^c   Brunet, Philippe ^a   Roumenov, Dimitri ^b   Dussol, Bertrand ^a   Barre, Jerome ^b   Duche, Jean Claude ^b   Albengres, Edith ^b   D'Athis, Philippe ^b   Chauvet Monges, Anne Marie ^a   Berland, Yvon ^a   Tillement, Jean Paul ^b  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^c Service de Pharmacologie   (France)

Author keywords

Cyclosporine A; Interleukin 2; Soluble interleukin 2 receptors; Trimetazidine

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; PREDNISONE; TRIMETAZIDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INTERACTION; FEMALE; HUMAN; KIDNEY ALLOGRAFT; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 15644365901     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00628.x     Document Type: Article

References (17)

1. Harpey C, Clauser P, Labrid C, et al. Timetazidine, a cellular anti-ischemic agent. Cardiovascular Drugs Reviews 1988; 6: 292-312.
2. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994; 37: 279-288.
3. Creagh T, Lanigan D, Dolan J, et al. Pharmacological manipulation of acute cyclosporin ischemic renal injury with trimetazidine. J Urol 1993; 149: 915-917.
4. Salducci MD, Chauvet-Monges AM, Tillement JP, et al. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria. J Pharmacol Exp Ther 1996; 277: 417-422.
5. Albengres E, Tillement JP, D'Athis P, et al. Lack of pharmacodynamic interaction between trimetazidine and cyclosporine A in human lymphoproliferative and mouse delayed hypersensitivity response models. Fundam Clin Pharmacol 1996; 3: 264-268.
6. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-635.
7. McMillan MA. Clinical pharmacokinetics of cyclosporin. Pharmacol Ther 1989; 42: 135-156.
8. Jackson PJ, Brownsill RD, Taylor AR, et al. Identification of trimetazidine metabolites in human urine and plasma. Xenobiotica 1996; 26: 221-228.
9. Courte S, Bromet N. Trace determination of trimetazidine in plasma by high-performance liquid chromatography using fluorescence detection. J Chromatogr 1981; 224: 162-167.
10. Awni WM. Pharmacodynamic monitoring of cyclosporin. Clin Pharmacokin 1992; 23: 428-448.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
12. Siegel S. Friedman test. In Nonparametric Statistics for the Behavioral Sciences, ed. Siegel S, Tokyo: MacGraw Hill, 1956: 166-173.
13. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-218.
14. Holt DW, Mueller EA, Kovarik JM, et al. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplant Proc 1994; 26: 2935-2939.
15. Plaza JJ, Blum G, Ortiz A, et al. Usefulness of serum interleukin-2 receptor levels in renal allograft recipients. Transplant Proc 1992; 24: 63-64.
16. Cornaby A, Simpson MA, Vann Rice R, et al. Interleukin-2 production in plasma and urine, plasma interleukin-2 receptor levels, and urine cytology as mean of monitoring renal allograft recipients. Transplant Proc 1988; 20: 108-110.
17. Tsunada SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokin 1996; 30: 107-140.